Incannex to trial drug for inflammatory conditions
Melbourne cannabinoid and psychedelic medicine manufacturer Incannex Healthcare will go ahead with phase 1 clinical trials of its combination anti-inflammatory pharmaceutical IHL-675A for the treatment of rheumatoid arthritis, inflammatory bowel disease and lung inflammation. IHL-675A is a combination cannabinoid drug comprising cannabidiol (‘CBD’) and hydroxychloroquine (‘HCQ’) which the company said outperforms either CBD and HCQ…
Details